Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells
Issued Date
2022-04-01
Resource Type
ISSN
02507005
eISSN
17917530
Scopus ID
2-s2.0-85127282821
Pubmed ID
35346997
Journal Title
Anticancer Research
Volume
42
Issue
4
Start Page
1785
End Page
1799
Rights Holder(s)
SCOPUS
Bibliographic Citation
Anticancer Research Vol.42 No.4 (2022) , 1785-1799
Suggested Citation
Chiraphapphaiboon W., Luangwattananun P., Panya A., Jirapongwattana N., Punnakitikashem P., Chieochansin T., Junking M., Yenchitsomanus P.T. Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells. Anticancer Research Vol.42 No.4 (2022) , 1785-1799. 1799. doi:10.21873/anticanres.15655 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/83782
Title
Cytotoxic T Cells Activated by Self-differentiated Monocytederived Dendritic Cells Against Multiple Myeloma Cells
Author's Affiliation
Other Contributor(s)
Abstract
Background/Aim: B cell maturation antigen (BCMA) is an ideal target for adoptive T cell therapy of multiple myeloma (MM). In this study, we evaluated self-differentiated monocyte-derived dendritic cells expressing BCMA (SD-DC-BCMA) to activate T cells for killing MM cells. Materials and Methods: Lentivirus-modified SD-DC-BCMA harboring tri-cistronic cDNAs encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4), and BCMA was generated. Cytotoxicity of T cells activated by SD-DC-BCMA against MM cells was evaluated. Results: T cells activated by SD-DC-BCMA exhibited a dose-dependent cytotoxicity against BCMA-expressing MM cells and produced high IFN-γ levels, compared to inactivated T cells or control T cells. A significantly higher killing ability of T cells activated by SD-DC-BCMA was further demonstrated in BCMA-overexpressing cells when compared with BCMA-negative cells. Conclusion: The potency of SD-DC-BCMA to activate T cells for antigen-specific cancer killing provides a framework for therapeutic application of adoptive T cell therapy in MM.